Assessing the progression of mild cognitive impairment to Alzheimer's disease: Current trends and future directions

Alzheimer's Research and Therapy

Volumn 2, Issue 5, 2010, Pages

  Brooks, Larry G ^a   Loewenstein, David A ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; COGNITION; DEMENTIA; DISEASE COURSE; EARLY INTERVENTION; FUTUROLOGY; HUMAN; LONGITUDINAL STUDY; MEMORY; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; NEUROIMAGING; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 77957744549     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt52     Document Type: Review

References (89)

1. American Psychiatric Association: Task Force on DSM-IV, Diagnostic and Statistical Manual of Mental Disorders: DSM-IV Washington, DC: American Psychiatric Association 4 1994
2. Neuropathological stageing of Alzheimer-related changes. H Braak E Braak, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
3. Mild cognitive impairment: clinical characterization and outcome. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen, Arch Neurol 1999 56 303 308 10.1001/archneur.56.3.303 10190820 (Pubitemid 29120227)
4. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. B Winblad K Palmer M Kivipelto V Jelic L Fratiglioni LO Wahlund A Nordberg L Backman M Albert O Almkvist H Arai H Basun K Blennow M de Leon C DeCarli T Erkinjuntti E Giacobini C Graff J Hardy C Jack A Jorm K Ritchie C van Duijn P Visser RC Petersen, J Intern Med 2004 256 240 246 10.1111/j.1365-2796.2004. 01380.x 15324367
5. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. JL Cummings R Doody C Clark, Neurology 2007 69 1622 1634 10.1212/01.wnl.0000295996.54210.69 17938373
6. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. S Larrieu L Letenneur JM Orgogozo C Fabrigoule H Amieva N Le Carret P Barberger-Gateau JF Dartigues, Neurology 2002 59 1594 1599 12451203
7. Classification criteria for mild cognitive impairment: a population-based validation study. K Ritchie S Artero J Touchon, Neurology 2001 56 37 42 11148233 (Pubitemid 32059649)
8. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. B Dubois HH Feldman C Jacova ST Dekosky P Barberger-Gateau J Cummings A Delacourte D Galasko S Gauthier G Jicha K Meguro J O'Brien F Pasquier P Robert M Rossor S Salloway Y Stern PJ Visser P Scheltens, Lancet Neurol 2007 6 734 746 10.1016/S1474-4422(07)70178-3 17616482
9. Medical decision-making capacity in mild cognitive impairment: a 3-year longitudinal study. OC Okonkwo HR Griffith JN Copeland K Belue S Lanza EY Zamrini LE Harrell JC Brockington D Clark R Raman DC Marson, Neurology 2008 71 1474 1480 10.1212/01.wnl.0000334301.32358.48 18981368
10. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. B Schmand HM Huizenga WA van Gool, Psychol Med 2010 40 135 145 10.1017/S0033291709991516 19863841
11. Differential episodic and semantic memory performance in Alzheimer's disease and vascular dementias. RD Vanderploeg RL Yuspeh JA Schinka, J Int Neuropsychol Soc 2001 7 563 573 10.1017/S135561770175504X 11459108
12. Semantic interference deficits and the detection of mild Alzheimer's disease and mild cognitive impairment without dementia. DA Loewenstein A Acevedo C Luis T Crum WW Barker R Duara, J Int Neuropsychol Soc 2004 10 91 100 10.1017/S1355617704101112 14751011
13. Mild cognitive impairment: transition between aging and Alzheimer's disease. RC Petersen, Neurologia 2000 15 93 101 10846869
14. Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. LA Rabin N Pare AJ Saykin MJ Brown HA Wishart LA Flashman RB Santulli, Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2009 16 357 376 19353345
15. Quantification of five neuropsychological approaches to defining mild cognitive impairment. AJ Jak MW Bondi L Delano-Wood C Wierenga J Corey-Bloom DP Salmon DC Delis, Am J Geriatr Psychiatry 2009 17 368 375 10.1097/JGP. 0b013e31819431d5 19390294
16. Redefining Alzheimer's disease symposium. T Phelps W Thies G McKhann M Albert R Sperling S DeKosky, Alzheimer's Association International Conference on Alzheimer's Disease 2010: Focused Topic Sessions: Redefining Alzheimer's Disease. Presented July 13, 2010. Honolulu, HI 2010 http://www.alz.org/research/ diagnostic-criteria/
17. The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly - a systematic review. J Stein M Luppa E Brahler HH Konig SG Riedel-Heller, Dement Geriatr Cogn Disord 2010 29 275 286 10.1159/000289779 20375509
18. Cognitive reserve and Alzheimer disease. Y Stern, Alzheimer Dis Assoc Disord 2006 20 69 S74 10.1097/00002093-200607001-00010 16917199
19. Mild cognitive impairment: directions for future research. CA Luis DA Loewenstein A Acevedo WW Barker R Duara, Neurology 2003 61 438 444 12939414
20. Using different memory cutoffs to assess mild cognitive impairment. DA Loewenstein A Acevedo R Ownby J Agron WW Barker R Isaacson S Strauman R Duara, Am J Geriatr Psychiatry 2006 14 911 919 10.1097/01.JGP.0000229651.62137.e2 17068313
21. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. PS Aisen RC Petersen MC Donohue A Gamst R Raman RG Thomas S Walter JQ Trojanowski LM Shaw LA Beckett CR Jack Jr W Jagust AW Toga AJ Saykin JC Morris RC Green MW Weiner, Alzheimers Dement 2010 6 239 246 10.1016/j.jalz.2010.03.006 20451872
22. Cognitive functioning in Alzheimer's and vascular dementia: a meta-analysis. JL Mathias J Burke, Neuropsychology 2009 23 411 423 10.1037/a0015384 19586206
23. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. BR Reed DM Mungas JH Kramer W Ellis HV Vinters C Zarow WJ Jagust HC Chui, Brain 2007 130 731 739 10.1093/brain/awl385 17267522
24. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. AD Hutchinson JL Mathias, J Neurol Neurosurg Psychiatry 2007 78 917 928 10.1136/jnnp.2006.100669 17371908
25. Cognitive profiles in Alzheimer's disease and in mild cognitive impairment of different etiologies. DA Loewenstein A Acevedo J Agron R Issacson S Strauman E Crocco WW Barker R Duara, Dement Geriatr Cogn Disord 2006 21 309 315 10.1159/000091522 16490966
26. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. BE Snitz ES O'Meara MC Carlson AM Arnold DG Ives SR Rapp J Saxton OL Lopez LO Dunn KM Sink ST DeKosky, JAMA 2009 302 2663 2670 10.1001/jama.2009.1913 20040554
27. Cognition, reserve, and amyloid deposition in normal aging. DM Rentz JJ Locascio JA Becker EK Moran E Eng RL Buckner RA Sperling KA Johnson, Ann Neurol 2010 67 353 364 10.1001/archneurol.2010.19 20373347
28. Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. L Rozzini BV Chilovi M Conti E Bertoletti I Delrio M Trabucchi A Padovani, Int J Geriatr Psychiatry 2007 22 1217 1222 10.1002/gps.1816 17562522
29. Declining financial capacity in mild cognitive impairment: a 1-year longitudinal study. KL Triebel R Martin HR Griffith J Marceaux OC Okonkwo L Harrell D Clark J Brockington A Bartolucci DC Marson, Neurology 2009 73 928 934 10.1212/WNL.0b013e3181b87971 19770468
30. Validity of direct assessment of functional status as a tool for measuring Alzheimer's disease severity. O Zanetti GB Frisoni L Rozzini A Bianchetti M Trabucchi, Age Ageing 1998 27 615 622 10.1093/ageing/27.5.615 12675100
31. Cognitive correlates of financial abilities in mild cognitive impairment. OC Okonkwo VG Wadley HR Griffith K Ball DC Marson, J Am Geriatr Soc 2006 54 1745 1750 10.1111/j.1532-5415.2006.00916.x 17087703
32. The relationship between neuropsychological performance and daily functioning in individuals with Alzheimer's disease: ecological validity of neuropsychological tests. ST Farias E Harrell C Neumann A Houtz, Arch Clin Neuropsychol 2003 18 655 672 14591439
33. The Clinical Dementia Rating (CDR): current version and scoring rules. JC Morris, Neurology 1993 43 2412 2414 8232972
34. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. SE O'Bryant LH Lacritz J Hall SC Waring W Chan ZG Khodr PJ Massman V Hobson CM Cullum, Arch Neurol 2010 67 746 749 10.1001/archneurol.2010.115 20558394
35. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. BC Dickerson RA Sperling BT Hyman MS Albert D Blacker, Arch Gen Psychiatry 2007 64 1443 1450 10.1001/archpsyc.64.12.1443 18056553
36. Prevalence of mild cognitive impairment by multiple classifications: the Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. M Ganguli CC Chang BE Snitz JA Saxton J Vanderbilt CW Lee, Am J Geriatr Psychiatry 2010 18 674 683 10.1097/JGP.0b013e3181cdee4f 20220597
37. Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects. EC Mormino JT Kluth CM Madison GD Rabinovici SL Baker BL Miller RA Koeppe CA Mathis MW Weiner WJ Jagust, Brain 2009 132 1310 1323 10.1093/brain/awn320 19042931
38. Staging dementia using Clinical Dementia Rating scale sum of boxes scores: a Texas Alzheimer's research consortium study. SE O'Bryant SC Waring CM Cullum J Hall L Lacritz PJ Massman PJ Lupo JS Reisch R Doody, Arch Neurol 2008 65 1091 1095 10.1001/archneur.65.8.1091 18695059
39. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. AM Fjell KB Walhovd C Fennema-Notestine LK McEvoy DJ Hagler D Holland JB Brewer AM Dale, J Neurosci 2010 30 2088 2101 10.1523/JNEUROSCI.3785-09.2010 20147537
40. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. SL Miller E Fenstermacher J Bates D Blacker RA Sperling BC Dickerson, J Neurol Neurosurg Psychiatry 2008 79 630 635 10.1136/jnnp.2007.124149 17846109
41. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. JC Morris CM Roe EA Grant D Head M Storandt AM Goate AM Fagan DM Holtzman MA Mintun, Arch Neurol 2009 66 1469 1475 10.1001/archneurol.2009.269 20008650
42. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project. H Ishii H Ishikawa K Meguro M Tashiro S Yamaguchi, Int Psychogeriatr 2009 21 148 156 10.1017/S1041610208008132 19040787
43. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. P Buchhave K Blennow H Zetterberg E Stomrud E Londos N Andreasen L Minthon O Hansson, PLoS One 2009 4 6294 10.1371/journal.pone.0006294 19609443
44. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. P Vemuri HJ Wiste SD Weigand LM Shaw JQ Trojanowski MW Weiner DS Knopman RC Petersen CR Jack Jr, Neurology 2009 73 287 293 10.1212/WNL.0b013e3181af79e5 19636048
45. Do CSF total tau, phosphorylated tau, and -amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. BS Diniz JA Pinto Junior OV Forlenza, World J Biol Psychiatry 2008 9 172 182 10.1080/15622970701535502 17886169
46. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. PJ Visser F Verhey DL Knol P Scheltens LO Wahlund Y Freund-Levi M Tsolaki L Minthon AK Wallin H Hampel K Burger T Pirttila H Soininen MO Rikkert MM Verbeek L Spiru K Blennow, Lancet Neurol 2009 8 619 627 10.1016/S1474-4422(09)70139-5 19523877
47. CSF tau/A42 ratio for increased risk of mild cognitive impairment: a follow-up study. G Li I Sokal JF Quinn JB Leverenz M Brodey GD Schellenberg JA Kaye MA Raskind J Zhang ER Peskind TJ Montine, Neurology 2007 69 631 639 10.1212/01.wnl.0000267428.62582.aa 17698783
48. Cerebrospinal fluid tau/-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. AM Fagan CM Roe C Xiong MA Mintun JC Morris DM Holtzman, Arch Neurol 2007 64 343 349 10.1001/archneur.64.3.noc60123 17210801
49. Cerebrospinal fluid amyloid 42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. D de Jong RW Jansen BP Kremer MM Verbeek, J Gerontol A Biol Sci Med Sci 2006 61 755 758 16870640
50. Association of low plasma A42/A40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. NR Graff -Radford JE Crook J Lucas BF Boeve DS Knopman RJ Ivnik GE Smith LH Younkin RC Petersen SG Younkin, Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377
51. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. AJ Mitchell, J Neurol Neurosurg Psychiatry 2009 80 966 975 10.1136/jnnp.2008.167791 19465413
52. Relationships between biomarkers in aging and dementia. WJ Jagust SM Landau LM Shaw JQ Trojanowski RA Koeppe EM Reiman NL Foster RC Petersen MW Weiner JC Price CA Mathis, Neurology 2009 73 1193 1199 10.1212/WNL. 0b013e3181bc010c 19822868
53. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. BJ Snider AM Fagan C Roe AR Shah EA Grant C Xiong JC Morris DM Holtzman, Arch Neurol 2009 66 638 645 10.1001/archneurol. 2009.55 19433664
54. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. E Stomrud O Hansson H Zetterberg K Blennow L Minthon E Londos, Arch Neurol 2010 67 217 223 10.1001/archneurol.2009.316 20142530
55. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. WJ Henneman H Vrenken J Barnes IC Sluimer NA Verwey MA Blankenstein M Klein NC Fox P Scheltens F Barkhof WM van der Flier, Neurology 2009 73 935 940 10.1212/WNL.0b013e3181b879ac 19770469
56. Cerebrospinal fluid -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. T Tapiola I Alafuzoff SK Herukka L Parkkinen P Hartikainen H Soininen T Pirttila, Arch Neurol 2009 66 382 389 10.1001/archneurol.2008.596 19273758
57. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. G De Meyer F Shapiro H Vanderstichele E Vanmechelen S Engelborghs PP De Deyn E Coart O Hansson L Minthon H Zetterberg K Blennow L Shaw JQ Trojanowski, Arch Neurol 2010 67 949 956 10.1001/archneurol. 2010.179 20697045
58. Longitudinal changes of CSF biomarkers in memory clinic patients. FH Bouwman WM van der Flier NS Schoonenboom EJ van Elk A Kok F Rijmen MA Blankenstein P Scheltens, Neurology 2007 69 1006 1011 10.1212/01.wnl.0000271375. 37131.04 17785669
59. No association of CSF biomarkers with APOE4, plaque and tangle burden in definite Alzheimer's disease. S Engelborghs K Sleegers P Cras N Brouwers S Serneels E De Leenheir JJ Martin E Vanmechelen C Van Broeckhoven PP De Deyn, Brain 2007 130 2320 2326 10.1093/brain/awm136 17586559
60. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. N Mattsson H Zetterberg O Hansson N Andreasen L Parnetti M Jonsson SK Herukka WM van der Flier MA Blankenstein M Ewers K Rich E Kaiser M Tsolaki E Mulugeta E Rosen D Aarsland PJ Visser J Schroder J Marcusson M de Leon H Hampel P Scheltens T Pirttila A Wallin ME Jonhagen L Minthon B Winblad K Blennow, JAMA 2009 302 385 393 10.1001/jama.2009.1064 19622817
61. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with A deposition. M Storandt MA Mintun D Head JC Morris, Arch Neurol 2009 66 1476 1481 10.1001/archneurol.2009.272 20008651
62. Basal cerebral metabolism may modulate the cognitive effects of A in mild cognitive impairment: an example of brain reserve. AD Cohen JC Price LA Weissfeld J James BL Rosario W Bi RD Nebes JA Saxton BE Snitz HA Aizenstein DA Wolk ST Dekosky CA Mathis WE Klunk, J Neurosci 2009 29 14770 14778 10.1523/JNEUROSCI.3669-09.2009 19940172
63. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. AM Fagan MA Mintun AR Shah P Aldea CM Roe RH Mach D Marcus JC Morris DM Holtzman, EMBO Mol Med 2009 1 371 380 10.1002/emmm.200900048 20049742
64. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. T Hedden KR Van Dijk JA Becker A Mehta RA Sperling KA Johnson RL Buckner, J Neurosci 2009 29 12686 12694 10.1523/JNEUROSCI.3189-09. 2009 19812343
65. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. T Grimmer G Henriksen HJ Wester H Forstl WE Klunk CA Mathis A Kurz A Drzezga, Neurobiol Aging 2009 30 1902 1909 10.1016/j.neurobiolaging.2008.01.016 18346821
66. Amyloid imaging in mild cognitive impairment subtypes. DA Wolk JC Price JA Saxton BE Snitz JA James OL Lopez HJ Aizenstein AD Cohen LA Weissfeld CA Mathis WE Klunk ST De-Kosky, Ann Neurol 2009 65 557 568 10.1002/ana.21598 19475670
67. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. WJ Jagust D Bandy K Chen NL Foster SM Landau CA Mathis JC Price EM Reiman D Skovronsky RA Koeppe, Alzheimers Dement 2010 6 221 229 10.1016/j.jalz.2010.03.003 20451870
68. 18F-FDG and PiB PET in cognitive impairment. VJ Lowe BJ Kemp CR Jack M Senjem S Weigand M Shiung G Smith D Knopman B Boeve B Mullan RC Petersen, J Nucl Med 2009 50 878 886 10.2967/jnumed.108.058529 19443597
69. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. CC Rowe KA Ellis M Rimajova P Bourgeat KE Pike G Jones J Fripp H Tochon-Danguy L Morandeau G O'Keefe R Price P Raniga P Robins O Acosta N Lenzo C Szoeke O Salvado R Head R Martins CL Masters D Ames VL Villemagne, Neurobiol Aging 2010 31 1275 1283 10.1016/j.neurobiolaging.2010.04. 007 20472326
70. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. CR Jack VJ Lowe SD Weigand HJ Wiste ML Senjem DS Knopman MM Shiung JL Gunter BF Boeve BJ Kemp M Weiner RC Petersen, Brain 2009 132 1355 1365 10.1093/brain/awp062 19339253
71. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. AJ Furst GD Rabinovici AH Rostomian T Steed A Alkalay C Racine BL Miller WJ Jagust, Neurobiol Aging 2010 20417582
72. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. MA Burack J Hartlein HP Flores L Taylor-Reinwald JS Perlmutter NJ Cairns, Neurology 2010 74 77 84 10.1212/WNL.0b013e3181c7da8e 20038776
73. Imaging amyloid deposition in Lewy body diseases. SN Gomperts DM Rentz E Moran JA Becker JJ Locascio WE Klunk CA Mathis DR Elmaleh T Shoup AJ Fischman BT Hyman JH Growdon KA Johnson, Neurology 2008 71 903 910 10.1212/01.wnl. 0000326146.60732.d6 18794492
74. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. EC Petrie DJ Cross D Galasko GD Schellenberg MA Raskind ER Peskind S Minoshima, Arch Neurol 2009 66 632 637 10.1001/archneurol.2009.59 19433663
75. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. L Mosconi R Mistur R Switalski M Brys L Glodzik K Rich E Pirraglia W Tsui S De Santi MJ de Leon, Neurology 2009 72 513 520 10.1212/01.wnl.0000333247.51383.43 19005175
76. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E 4 allele. JB Langbaum K Chen RJ Caselli W Lee C Reschke D Bandy GE Alexander CM Burns AW Kaszniak SA Reeder JJ Corneveaux AN Allen J Pruzin MJ Huentelman AS Fleisher EM Reiman, Arch Neurol 2010 67 462 468 10.1001/archneurol.2010.30 20385913
77. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. RJ Caselli K Chen W Lee GE Alexander EM Reiman, Arch Neurol 2008 65 1231 1236 10.1001/archneurol.2008.1 18779428
78. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. D Anchisi B Borroni M Franceschi N Kerrouche E Kalbe B Beuthien-Beumann S Cappa O Lenz S Ludecke A Marcone R Mielke P Ortelli A Padovani O Pelati A Pupi E Scarpini S Weisenbach K Herholz E Salmon V Holthoff S Sorbi F Fazio D Perani, Arch Neurol 2005 62 1728 1733 10.1001/archneur.62.11.1728 16286547
79. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease. L Ercoli P Siddarth SC Huang K Miller SY Bookheimer BC Wright ME Phelps G Small, Arch Gen Psychiatry 2006 63 442 448 10.1001/archpsyc.63.4.442 16585474
80. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? W Jagust B Reed D Mungas W Ellis C Decarli, Neurology 2007 69 871 877 10.1212/01.wnl.0000269790.05105.16 17724289
81. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. B Kuczynski B Reed D Mungas M Weiner HC Chui W Jagust, Arch Neurol 2008 65 650 655 10.1001/archneur.65.5.650 18474742
82. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. NL Foster JL Heidebrink CM Clark WJ Jagust SE Arnold NR Barbas CS DeCarli RS Turner RA Koeppe R Higdon S Minoshima, Brain 2007 130 2616 2635 10.1093/brain/awm177 17704526
83. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. CR McDonald LK McEvoy L Gharapetian C Fennema-Notestine DJ Hagler D Holland A Koyama JB Brewer AM Dale, Neurology 2009 73 457 465 10.1212/WNL.0b013e3181b16431 19667321
84. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. JL Whitwell MM Shiung SA Przybelski SD Weigand DS Knopman BF Boeve RC Petersen CR Jack Jr, Neurology 2008 70 512 520 10.1212/01.wnl.0000280575.77437.a2 17898323
85. Longitudinal study of the transition from healthy aging to Alzheimer disease. DK Johnson M Storandt JC Morris JE Galvin, Arch Neurol 2009 66 1254 1259 10.1001/archneurol.2009.158 19822781
86. Trajectories of brain loss in aging and the development of cognitive impairment. NE Carlson MM Moore A Dame D Howieson LC Silbert JF Quinn JA Kaye, Neurology 2008 70 828 833 10.1212/01.wnl.0000280577.43413.d9 18046010
87. Con: Can biomarkers be gold standards in Alzheimer's disease? K Rockwood, Alzheimers Res Ther 2010 2 16 10.1186/alzrt40 20587007
88. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. DP Devanand A Mikhno GH Pelton K Cuasay G Pradhaban JS Kumar N Upton R Lai RN Gunn V Libri X Liu RV Heertum JJ Mann RV Parsey, J Geriatr Psychiatry Neurol 2010 23 185 198 10.1177/0891988710363715 20430977
89. Comparing predictors of conversion and decline in mild cognitive impairment. SM Landau D Harvey CM Madison EM Reiman NL Foster PS Aisen RC Petersen LM Shaw JQ Trojanowski CR Jack Jr MW Weiner WJ Jagust, Neurology 2010 75 230 238 10.1212/WNL.0b013e3181e8e8b8 20592257